Cysteine 390 mutation of the TSH receptor modulates its ectodomain as an inverse agonist on the serpentine domain with decrease in basal constitutive activity

[1]  R. Paschke,et al.  Identification of a Novel Epitope in the Thyroid-stimulating Hormone Receptor Ectodomain Acting as Intramolecular Signaling Interface*[boxs] , 2004, Journal of Biological Chemistry.

[2]  L. Seah,et al.  Thyroid autoantibody profiles in ophthalmic dominant and thyroid dominant Graves’ disease differ and suggest ophthalmopathy is a multiantigenic disease , 2004, Clinical endocrinology.

[3]  L. Pardo,et al.  A molecular dissection of the glycoprotein hormone receptors. , 2004, Trends in biochemical sciences.

[4]  Arthur Christopoulos,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on Terms and Symbols in Quantitative Pharmacology , 2003, Pharmacological Reviews.

[5]  N. Harii,et al.  Thyrotropin Receptor Autoantibodies (TSHRAbs): Epitopes, Origins and Clinical Significance , 2003, Autoimmunity.

[6]  R. Pierson,et al.  Ovarian hyperstimulation syndrome due to a mutation in the follicle-stimulating hormone receptor. , 2003, The New England journal of medicine.

[7]  F. Savagner,et al.  A chorionic gonadotropin-sensitive mutation in the follicle-stimulating hormone receptor as a cause of familial gestational spontaneous ovarian hyperstimulation syndrome. , 2003, The New England journal of medicine.

[8]  L. Pardo,et al.  Glycoprotein hormone receptors: determinants in leucine‐rich repeats responsible for ligand specificity , 2003, The EMBO journal.

[9]  A. Bergmann,et al.  Generation of a mouse monoclonal TSH receptor antibody with stimulating activity. , 2002, Biochemical and biophysical research communications.

[10]  S. Costagliola,et al.  Activation of the cAMP pathway by the TSH receptor involves switching of the ectodomain from a tethered inverse agonist to an agonist. , 2002, Molecular endocrinology.

[11]  S. Costagliola,et al.  Tyrosine sulfation is required for agonist recognition by glycoprotein hormone receptors , 2002, The EMBO journal.

[12]  S. Costagliola,et al.  Effects of mutations involving the highly conserved S281HCC motif in the extracellular domain of the thyrotropin (TSH) receptor on TSH binding and constitutive activity. , 2001, Endocrinology.

[13]  Kunihiko Tanaka,et al.  A Full Biological Response to Autoantibodies in Graves' Disease Requires a Disulfide-bonded Loop in the Thyrotropin Receptor N Terminus Homologous to a Laminin Epidermal Growth Factor-like Domain* , 2001, The Journal of Biological Chemistry.

[14]  T. Akamizu,et al.  Hashimoto's thyroiditis with heterogeneous antithyrotropin receptor antibodies: unique epitopes may contribute to the regulation of thyroid function by the antibodies. , 2000, The Journal of clinical endocrinology and metabolism.

[15]  U. Gether.  Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[16]  P. Kopp,et al.  Substitutions of tyrosine 601 in the human thyrotropin receptor result in increase or loss of basal activation of the cyclic adenosine monophosphate pathway and disrupt coupling to Gq/11. , 2000, Thyroid : official journal of the American Thyroid Association.

[17]  Eng,et al.  Differences in the levels of TSH‐binding inhibitor immunoglobulins in goitrous and agoitrous autoimmune thyroiditis after twelve months of l‐thyroxine therapy , 1999, Clinical endocrinology.

[18]  J. Parma,et al.  Familial gestational hyperthyroidism caused by a mutant thyrotropin receptor hypersensitive to human chorionic gonadotropin. , 1998, The New England journal of medicine.

[19]  B. Rapoport,et al.  The Thyrotropin (TSH)-Releasing Hormone Receptor: Interaction with TSH and Autoantibodies , 1998 .

[20]  S. Costagliola,et al.  Production of bioactive amino‐terminal domain of the thyrotropin receptor via insertion in the plasma membrane by a glycosylphosphatidylinositol anchor , 1998, FEBS letters.

[21]  S. Costagliola,et al.  Genetic immunization against the human thyrotropin receptor causes thyroiditis and allows production of monoclonal antibodies recognizing the native receptor. , 1998, Journal of immunology.

[22]  K. Tanaka,et al.  Thyrotropin Receptor Cleavage at Site 1 Does Not Involve a Specific Amino Acid Motif but Instead Depends on the Presence of the Unique, 50 Amino Acid Insertion* , 1998, The Journal of Biological Chemistry.

[23]  E. Milgrom,et al.  Cleavage and shedding of the TSH receptor. , 1997, European journal of endocrinology.

[24]  K. Tanaka,et al.  Evidence that the thyrotropin receptor ectodomain contains not one, but two, cleavage sites. , 1997, Endocrinology.

[25]  B. Rapoport,et al.  Is receptor cleavage into two subunits necessary for thyrotropin action? , 1996, Biochemical and biophysical research communications.

[26]  P P Humphrey,et al.  International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. , 1994, Pharmacological reviews.

[27]  B. Westermark,et al.  Point mutations of the thyrotropin receptor determining structural requirements for its ability to bind thyrotropin and to stimulate adenylate cyclase activity. , 1994, Biochemical and biophysical research communications.

[28]  T. Akamizu,et al.  Further studies of amino acids (268-304) in thyrotropin (TSH)--lutropin/chorionic gonadotropin (LH/CG) receptor chimeras: cysteine-301 is important in TSH binding and receptor tertiary structure. , 1994, Thyroid : official journal of the American Thyroid Association.

[29]  T. Akamizu,et al.  Use of thyrotropin receptor (TSHR) mutants to detect stimulating TSHR antibodies in hypothyroid patients with idiopathic myxedema, who have blocking TSHR antibodies. , 1993, The Journal of clinical endocrinology and metabolism.

[30]  L. Kohn,et al.  Identification of thyroid-stimulating antibody-specific interaction sites in the N-terminal region of the thyrotropin receptor. , 1993, Molecular endocrinology.

[31]  T. Akamizu,et al.  Role of cysteine residues in the extracellular domain and exoplasmic loops of the transmembrane domain of the TSH receptor: effect of mutation to serine on TSH receptor activity and response to thyroid stimulating autoantibodies. , 1992, Biochemical and biophysical research communications.

[32]  T. Akamizu,et al.  Further characterization of a high affinity thyrotropin binding site on the rat thyrotropin receptor which is an epitope for blocking antibodies from idiopathic myxedema patients but not thyroid stimulating antibodies from Graves' patients. , 1991, Biochemical and biophysical research communications.